{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"}],"units":"Participants"}],"description":"A TEAE is any adverse event (AE) either reported for the first time or worsening of a pre-existing event after the first dose of study treatment.","groups":[{"description":"INCAGN01876 in combination with pembrolizumab and epacadostat","id":"OG000","title":"INCAGN01876 + Pembrolizumab + Epacadostat"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The FAS includes all participants enrolled in the study who received at least 1 dose of INCAGN01876, pembrolizumab, or epacadostat.","reportingStatus":"POSTED","timeFrame":"Screening through 60 days after end of treatment, up to approximately 18 months","title":"Phase 1 and Phase 2: Participants With Treatment-Emergent Adverse Events (TEAEs) [Safety and Tolerability]","type":"PRIMARY","unitOfMeasure":"Participants"}